HOB Biotech Group Corp Ltd (688656) - Total Assets
Based on the latest financial reports, HOB Biotech Group Corp Ltd (688656) holds total assets worth CN¥965.27 Million CNY (≈ $141.25 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See HOB Biotech Group Corp Ltd book value and equity for net asset value and shareholders' equity analysis.
HOB Biotech Group Corp Ltd - Total Assets Trend (2016–2024)
This chart illustrates how HOB Biotech Group Corp Ltd's total assets have evolved over time, based on quarterly financial data.
HOB Biotech Group Corp Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
HOB Biotech Group Corp Ltd's total assets of CN¥965.27 Million consist of 28.3% current assets and 71.7% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 11.8% |
| Accounts Receivable | CN¥50.97 Million | 4.9% |
| Inventory | CN¥111.22 Million | 10.8% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥10.08 Million | 1.0% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2016–2024)
This chart illustrates how HOB Biotech Group Corp Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 688656 company net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: HOB Biotech Group Corp Ltd's current assets represent 28.3% of total assets in 2024, a decrease from 42.3% in 2016.
- Cash Position: Cash and equivalents constituted 11.8% of total assets in 2024, up from 10.4% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2016.
- Asset Diversification: The largest asset category is inventory at 10.8% of total assets.
HOB Biotech Group Corp Ltd Competitors by Total Assets
Key competitors of HOB Biotech Group Corp Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Jafron Biomedical Co Ltd
SHE:300529
|
China | CN¥5.54 Billion |
|
Sinocare Inc
SHE:300298
|
China | CN¥6.25 Billion |
|
Shanghai Kinetic Medical Co
SHE:300326
|
China | CN¥3.38 Billion |
|
Eurobio Scientific SA
PA:ALERS
|
France | €259.11 Million |
|
EBR Systems Inc
AU:EBR
|
Australia | AU$97.29 Million |
|
PULSION Medical Systems SE
MU:PUS
|
Germany | €35.15 Million |
|
Aroa Biosurgery Ltd
AU:ARX
|
Australia | AU$95.27 Million |
|
Medprin Regenerative Medical Technologies Co. Ltd.
SHE:301033
|
China | CN¥805.10 Million |
HOB Biotech Group Corp Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.89 | 1.53 | 2.51 |
| Quick Ratio | 1.07 | 0.94 | 1.53 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥118.60 Million | CN¥98.42 Million | CN¥95.43 Million |
HOB Biotech Group Corp Ltd - Advanced Valuation Insights
This section examines the relationship between HOB Biotech Group Corp Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 11.30 |
| Latest Market Cap to Assets Ratio | 1.22 |
| Asset Growth Rate (YoY) | 8.8% |
| Total Assets | CN¥1.03 Billion |
| Market Capitalization | $1.26 Billion USD |
Valuation Analysis
Above Book Valuation: The market values HOB Biotech Group Corp Ltd's assets above their book value (1.22x), reflecting positive investor sentiment about the company's future prospects.
Positive Asset Growth: HOB Biotech Group Corp Ltd's assets grew by 8.8% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for HOB Biotech Group Corp Ltd (2016–2024)
The table below shows the annual total assets of HOB Biotech Group Corp Ltd from 2016 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥1.03 Billion ≈ $151.13 Million |
+8.80% |
| 2023-12-31 | CN¥949.26 Million ≈ $138.91 Million |
+0.50% |
| 2022-12-31 | CN¥944.56 Million ≈ $138.22 Million |
+9.33% |
| 2021-12-31 | CN¥863.92 Million ≈ $126.42 Million |
+191.46% |
| 2020-12-31 | CN¥296.41 Million ≈ $43.37 Million |
+4.67% |
| 2019-12-31 | CN¥283.18 Million ≈ $41.44 Million |
+25.73% |
| 2018-12-31 | CN¥225.22 Million ≈ $32.96 Million |
+56.16% |
| 2017-12-31 | CN¥144.22 Million ≈ $21.10 Million |
+15.70% |
| 2016-12-31 | CN¥124.65 Million ≈ $18.24 Million |
-- |
About HOB Biotech Group Corp Ltd
HOB Biotech Group Corp.,Ltd. operates as a in vitro diagnostic company in China and internationally. It provides diagnostic tools, such as line immune, enzyme-linked immunosorbent, and chemiluminescent paramagnetic microparticle immuno assays to laboratories and hospitals for the improvement of allergy and autoimmune disease patient care. The company was founded in 2009 and is based in Suzhou, Ch… Read more